Clinical trial
A Double-Blind, Single Center, Randomized, Placebo-Controlled Study of BMS-984923 in Participants With Parkinson's Disease
NCT06309147 is registered in ClinicalTrials.gov with Allyx Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Single Center, Randomized, Placebo-Controlled Study of BMS-984923 in Participants With Parkinson's Disease
- Lead sponsor
- Allyx Therapeutics
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 15, 2024
- Completion date
- July 15, 2025
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.